4D Molecular Therapeutics (NASDAQ: FDMT) reported its 2025 financial results, ending the year with $514 million in cash, cash equivalents and marketable securities. Collaboration and license revenue totaled $85 million, driven entirely by an $85 million upfront payment from Otsuka for the Asia‑Pacific rights to the company’s lead candidate, 4D‑150. Research and development expenses rose to $196 million from $141 million in 2024, reflecting the launch of Phase 3 trials for 4D‑150 in wet age‑related macular degeneration. General and administrative costs increased modestly to $49 million, up from $47 million, while the company posted a net loss of $140 million, a reduction from the $161 million loss reported in 2024.
The $85 million Otsuka payment, combined with an $11 million commitment from the Cystic Fibrosis Foundation—of which $7.5 million was received upfront in October 2025—provides a non‑dilutive funding stream that is expected to support operations through the second half of 2028. The increase in R&D spend is largely attributable to the execution of the 4FRONT‑1 Phase 3 trial, which completed enrollment in February 2026, and to early‑stage work on 4D‑710 for cystic fibrosis. The higher expenses offset the revenue boost, leaving the company with a narrowed but still substantial net loss.
The results underscore a strategic de‑risking of the pipeline. The Otsuka partnership not only injects capital but also validates 4D‑150’s clinical potential, positioning the therapy as a potential “backbone” treatment that could reduce injection frequency for retinal vascular diseases. The extended cash runway gives the company flexibility to pursue additional milestones, including the first pivotal data readout for wet AMD expected in the first half of 2027, and to prepare for potential regulatory filings and commercial launch in 2026 and beyond.
CEO David Kirn said, “2025 was a transformative year for 4DMT highlighted by meaningful progress advancing 4D‑150 with rapid Phase 3 trial enrollment, presenting strong 4D‑150 Phase 1/2 durability data, entering a strategic partnership with Otsuka and strengthening our financial position.” He added, “These achievements position us well for execution in 2026 and beyond as we continue toward our goal of redefining the treatment paradigm for retinal vascular disease with 4D‑150, with our first pivotal data readout for wet AMD expected in the first half of 2027.”
Looking ahead, the company maintains its guidance that the cash balance will support operations through the second half of 2028, and it signals confidence in the 4D‑150 pipeline. The company’s focus remains on completing the Phase 3 trial, securing regulatory approvals, and preparing for commercialization, while continuing to advance 4D‑710 and other early‑stage programs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.